SEARCH

SEARCH BY CITATION

References

  • Acquas E., Pisanu A., Spiga S., Plumitallo A., Zernig G. and Di Chiara G. (2007) Differential effects of intravenous R, S-(+/-)-3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and its S(+)- and R(-)-enantiomers on dopamine transmission and extracellular signal regulated kinase phosphorylation (pERK) in the rat nucleus accumbens shell and core. J. Neurochem. 102, 121132.
  • von Ameln N. and von Ameln-Mayerhofer A. (2010) Atypical development&of behavioural sensitization to 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) in adolescent rats and its expression in adulthood: role of the MDMA chirality. Addict. Biol. 15, 3544.
  • Borch R. F., Bernstein M. D. and Dupont Durst H. (1971) Cyanohydridoborate anion as a selective reducing agent. J. Am. Chem. Soc. 93, 28972904.
  • Capela J. P., Macedo C., Branco P. S. et al. (2007) Neurotoxicity mechanisms of thioether ecstasy metabolites. Neuroscience 146, 17431757.
  • Carta A. R., Kachroo A., Schintu N., Xu K., Schwarzschild M. A., Wardas J. and Morelli M. (2009) Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurochem. 111, 14781489.
  • Colado M. I., Granados R., O'Shea E., Esteban B. and Green A. R. (1998) Role of hyperthermia in the protective action of clomethiazole against MDMA (‘ecstasy’)-induced neurodegeneration, comparison with the novel NMDA channel blocker AR-R15896AR. Br. J. Pharmacol. 124, 479484.
  • Delle Donne K. T. and Sonsalla P. K. (1994) Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation. J. Pharmacol. Exp. Ther. 271, 13201326.
  • Fantegrossi W. E. (2008) In vivo pharmacology of MDMA and its enantiomers in rhesus monkeys. Exp. Clin. Psychopharmacol. 16, 112.
  • Fantegrossi W. E., Godlewski T., Karabenick R. L., Stephens J. M., Ullrich T., Rice K. C. and Woods J. H. (2003) Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine (“ecstasy”) and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology 166, 202211.
  • Fantegrossi W. E., Murai N., Mathúna B. O., Pizarro N. and de la Torre R. (2009) Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and its enantiomers in mice: pharmacokinetic considerations. J. Pharmacol. Exp. Ther. 329, 10061015.
  • Frau L., Borsini F., Wardas J., Khairnar A. S., Schintu N. and Morelli M. (2011) Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease. Synapse 65, 181188.
  • Gluck M. R., Moy L. Y., Jayatilleke E., Hogan K. A., Manzino L. and Sonsalla P. K. (2001) Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment. J. Neurochem. 79, 152160.
  • Granado N., Escobedo I., O'Shea E., Colado I. and Moratalla R. (2008a) Early loss of dopaminergic terminals in striosomes after MDMA administration to mice. Synapse 62, 8084.
  • Granado N., O'Shea E., Bove J., Vila M., Colado M. I. and Moratalla R. (2008b) Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice. J. Neurochem. 107, 11021112.
  • Green A. R., Mechan A. O., Elliott J. M., O'Shea E. and Colado M. I. (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol. Rev. 55, 463508.
  • Halliday G. M. and Stevens C. H. (2011) Glia: initiators and progressors of pathology in Parkinson's disease. Mov. Disord. 26, 617.
  • Hass H. B., Susie A. G. and Heider R. L. (1950) Nitro alkene derivatives. J. Org. Chem. 15, 814.
  • Hayat S., Williams R. J. and Rattray M. (2006) Serotonin transporter expression is not sufficient to confer cytotoxicity to 3,4-methylenedioxymethamphetamine (MDMA) in vitro. J. Psychopharmacol. 20, 257263.
  • Hiramatsu M., Nabeshima T., Kameyama T., Maeda Y. and Cho A. K. (1989) The effect of optical isomers of 3,4-methylenedioxymethamphetamine (MDMA) on stereotyped behavior in rats. Pharmacol. Biochem. Behav. 33, 343347.
  • Johnson E. A., Shvedova A. A., Kisin E., O'Callaghan J. P., Kommineni C. and Miller D. B. (2002) d-MDMA during vitamin E deficiency: effects on dopaminergic neurotoxicity and hepatotoxicity. Brain Res. 933, 150163.
  • Khairnar A., Plumitallo A., Frau L., Schintu N. and Morelli M. (2010) Caffeine enhances astroglia and microglia reactivity induced by 3,4-methylenedioxymethamphetamine (‘ecstasy’) in mouse brain. Neurotox. Res. 17, 435439.
  • Lebsanft H. B., Kohles T., Kovar K. A. and Schmidt W. J. (2005) 3,4-Methylenedioxymethamphetamine counteracts akinesia enantioselectively in rat rotational behavior and catalepsy. Synapse 55, 148155.
  • Lim H. K., Su Z. and Foltz R. L. (1993) Stereoselective disposition: enantioselective quantitation of 3,4-(methylenedioxy) methamphetamine and three of its metabolites by gas chromatography/electron capture negative ion chemical ionization mass spectrometry. Biol. Mass Spectrom. 22, 403411.
  • Mechan A. O., O'Shea E., Elliott J. M., Colado M. I. and Green A. R. (2001) A neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) to rats results in a long-term defect in thermoregulation. Psychopharmacology 155, 413418.
  • Meyer M. R. and Maurer H. H. (2009) Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation. Chem. Res. Toxicol. 22, 12051211.
  • Meyer A., Mayerhofer A., Kovar K. A. and Schmidt W. J. (2002) Enantioselective metabolism of the designer drugs 3,4-methylenedioxymethamphetamine (‘ecstasy’) and 3,4-methylenedioxyethylamphetamine (‘eve’) isomers in rat brain and blood. Neurosci. Lett. 330, 193197.
  • Miller D. B. and O'Callaghan J. P. (1995) The role of temperature, stress, and other factors in the neurotoxicity of the substituted amphetamines 3,4-methylenedioxymethamphetamine and fenfluramine. Mol. Neurobiol. 11, 177192.
  • Nichols D. E., Hoffman A. J., Oberlender R. A., Jacob P. III and Shulgin A. T. (1986) Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class. J. Med. Chem. 29, 20092015.
  • O'Callaghan J. P. and Miller D. B. (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 270, 741751.
  • O'Callaghan J. P. and Sriram K. (2005) Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity. Expert Opin. Drug Saf. 4, 433442.
  • Paxinos G. and Franklin K. B. J. (2001) The Mouse Brain in Stereotaxic Coordinates. Academic Press, San Diego.
  • Rattray M. (1991) Ecstasy: towards an understanding of the biochemical basis of the actions of MDMA. Essays Biochem. 26, 7787.
  • Reveron M. E., Monks T. J. and Duvauchelle C. L. (2005) Age-dependent (+)MDMA-mediated neurotoxicity in mice. Neurotoxicology 26, 10311040.
  • Schenk S. (2009) MDMA self-administration in laboratory animals: a summary of the literature and proposal for future research. Neuropsychobiology 60, 130136.
  • Schifano F. (2004) A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities. Psychopharmacology 173, 242248.
  • Taffe M. A., Lay C. C., Von Huben S. N., Davis S. A., Crean R. D. and Katner S. N. (2006) Hyperthermia induced by 3,4-methylenedioxymethamphetamine in unrestrained rhesus monkeys. Drug Alcohol Depend. 82, 276281.
  • Touriño C., Zimmer A. and Valverde O. (2010) THC prevents MDMA neurotoxicity in mice. PLoS ONE 5, e9143.
  • Young R. and Glennon R. A. (2008) MDMA (N-methyl-3,4-methylenedioxyamphetamine) and its stereoisomers: Similarities and differences in behavioral effects in an automated activity apparatus in mice. Pharmacol. Biochem. Behav. 88, 318331.
  • Zhang L., Shirayama Y., Shimizu E., Iyo M. and Hashimoto K. (2006) Protective effects of minocycline on 3,4-methylenedioxymethamphetamine-induced neurotoxicity in serotonergic and dopaminergic neurons of mouse brain. Eur. J. Pharmacol. 544, 19.